Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study.
about
PBPK modeling and simulation in drug research and developmentPhysiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model VerificationAssessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data.Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects.Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib.Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjectsRitonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiolPredicting drug-drug interactions: an FDA perspectiveClinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir.Modeling and predicting drug pharmacokinetics in patients with renal impairment.Use of physiologically based pharmacokinetic modeling for assessment of drug-drug interactions.Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.Individualization of drug therapy: history, present state, and opportunities for the future.Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach.Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies.Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies.Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor.Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction.Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics.Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions.Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitorsEffects of Ketoconazole on the Pharmacokinetics of Mifepristone, a Competitive Glucocorticoid Receptor Antagonist, in Healthy Men.CYP3A4-based drug-drug interaction: CYP3A4 substrates' pharmacokinetic properties and ketoconazole dose regimen effect.In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans.A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.Bioavailability considerations in evaluating drug-drug interactions using the population pharmacokinetic approach.Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions.Assessment of drug-drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase.Itraconazole, a P-Glycoprotein and CYP3A4 Inhibitor, Markedly Raises the Plasma Concentrations and Enhances the Renin-Inhibiting Effect of Aliskiren
P2860
Q28066513-CFFBB8EA-092B-4203-A619-2FC2A10B98BBQ28088352-8BBBE5D0-BA97-4AF8-8EC8-7DBD68842A6CQ30688345-64B58A2C-B117-4B44-A27D-4145D5BC5637Q34308118-95647711-93F6-4D02-928C-177671CE453EQ34476096-BA2F8012-DFE6-4357-A279-25740527513CQ34556733-64316C7A-0AC8-4C58-8E4C-F90AA3C11083Q34570949-52E38316-8136-4696-968D-48E435AA5CADQ36072448-5438AB69-EFE5-4B33-9F53-2B98CDE4F181Q36410060-12141BE1-2C8D-43AF-B0F5-971A38EA344CQ37214533-4F088BC7-48A3-46DD-8D45-15A9D736E46BQ37846672-DBE7B3ED-3F85-419F-9A65-B6484A6EA6C5Q37960638-7C2BB880-47CB-488B-B27B-E947919072EAQ37998136-360C6B3B-8F82-4140-9DBF-9EC1B643B947Q38014312-AC6359E0-0177-4238-B866-E17F8D6B9F18Q38040697-193B0887-9573-46E8-A4FD-7C6ECBC2247CQ38087695-2122B85B-F9F0-45A4-8CFD-2F148C31207FQ38420688-525B59E7-D8C4-44D7-AC02-6547E605A5A3Q38516237-887EAB26-6223-499E-BF3C-D099C7937D59Q39643626-47B8F0D7-B9A1-4013-879E-BCAA9B9CCFF8Q40183320-B13B4AAA-B637-4869-A116-CAE5B7B045E2Q40672523-F3E4E3C0-77FA-48EC-ADB6-069364875D63Q40991626-C919CE69-0B04-445A-A28D-CD9EAEF2CE55Q41904888-1A8EB00D-549D-4E04-856F-1C225B76D21DQ42597779-2569DC0D-E2ED-49FF-A2C9-1AB842075691Q42696417-15E1AC27-3203-4A7F-9C56-38FEA90BA22FQ47792940-A90A709A-141F-41FE-BD76-0BE1190696F5Q47888898-7657CD3F-5478-4070-93AB-C868636401CDQ48010621-78D53897-4010-430E-8C83-1287B9C9D455Q48325069-F4EA0B8A-76D6-4BDC-943D-24D7B882C130Q48677705-57AF3913-4406-4E4A-B113-F212F1BD62F8Q49345557-972C5135-0288-4387-9BE4-DF51918C66BEQ57825127-4CB700AC-99D6-4D6F-983B-4052F4A6C7D4
P2860
Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Quantitative evaluation of pha ...... oconazole: a simulation study.
@en
Quantitative evaluation of pha ...... oconazole: a simulation study.
@nl
type
label
Quantitative evaluation of pha ...... oconazole: a simulation study.
@en
Quantitative evaluation of pha ...... oconazole: a simulation study.
@nl
prefLabel
Quantitative evaluation of pha ...... oconazole: a simulation study.
@en
Quantitative evaluation of pha ...... oconazole: a simulation study.
@nl
P2093
P2860
P356
P1476
Quantitative evaluation of pha ...... oconazole: a simulation study.
@en
P2093
Isabelle Ragueneau-Majlessi
John M Strong
Kellie S Reynolds
Kenneth E Thummel
Rene H Levy
Shiew-Mei Huang
P2860
P304
P356
10.1177/0091270008331196
P577
2009-03-01T00:00:00Z